company background image
2PU logo

Pulmatrix DB:2PU Stock Report

Last Price

€5.55

Market Cap

€21.0m

7D

3.7%

1Y

214.6%

Updated

23 Dec, 2024

Data

Company Financials

2PU Stock Overview

A clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. More details

2PU fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Pulmatrix, Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Pulmatrix
Historical stock prices
Current Share PriceUS$5.55
52 Week HighUS$7.30
52 Week LowUS$1.41
Beta1.54
1 Month Change-3.48%
3 Month Change193.65%
1 Year Change214.63%
3 Year Change-25.50%
5 Year Change-62.24%
Change since IPO-99.17%

Recent News & Updates

Recent updates

Shareholder Returns

2PUDE PharmaceuticalsDE Market
7D3.7%-2.2%-2.0%
1Y214.6%-15.6%6.9%

Return vs Industry: 2PU exceeded the German Pharmaceuticals industry which returned -15.6% over the past year.

Return vs Market: 2PU exceeded the German Market which returned 6.9% over the past year.

Price Volatility

Is 2PU's price volatile compared to industry and market?
2PU volatility
2PU Average Weekly Movement32.5%
Pharmaceuticals Industry Average Movement5.5%
Market Average Movement4.9%
10% most volatile stocks in DE Market11.3%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 2PU's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 2PU's weekly volatility has increased from 18% to 33% over the past year.

About the Company

FoundedEmployeesCEOWebsite
200322Peter Ludlumwww.pulmatrix.com

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.

Pulmatrix, Inc. Fundamentals Summary

How do Pulmatrix's earnings and revenue compare to its market cap?
2PU fundamental statistics
Market cap€21.00m
Earnings (TTM)-€9.25m
Revenue (TTM)€9.59m

2.2x

P/S Ratio

-2.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2PU income statement (TTM)
RevenueUS$10.01m
Cost of RevenueUS$10.68m
Gross Profit-US$671.00k
Other ExpensesUS$8.99m
Earnings-US$9.66m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.64
Gross Margin-6.71%
Net Profit Margin-96.51%
Debt/Equity Ratio0%

How did 2PU perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 12:38
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pulmatrix, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Robert WassermanDawson James Securities
Andrew FeinH.C. Wainwright & Co.
Anita DushyanthZacks Investment Research Inc.